Vimnerixin

• CAT Number: I045080
• CAS Number: 1418112-77-2
• Molecular Formula: C19H25FN4O5S2
• Molecular Weight: 472.55
• Purity: ≥95%
• Synonyms: N-[6-[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy-2-[(4-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]-3-methylazetidine-1-sulfonamide
• InChI: InChI=1S/C19H25FN4O5S2/c1-12-8-24(9-12)31(27,28)23-17-7-18(29-13(2)16(26)10-25)22-19(21-17)30-11-14-3-5-15(20)6-4-14/h3-7,12-13,16,25-26H,8-11H2,1-2H3,(H,21,22,23)/t13-,16+/m1/s1
• InChIKey: UCCNQCNIPRKLRP-CJNGLKHVSA-N
• SMILES: CC1CN(C1)S(=O)(=O)NC2=CC(=NC(=N2)SCC3=CC=C(C=C3)F)OC(C)C(CO)O

Vimnerixin (AZD4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). Vimnerixin has the potential for the research of inflammatory disease[1].
Assessment of Pharmacokinetics (PK) profile of Vimnerixin in rat and dog[1].

In Vivo PK
Rat
Dog

Predicted hepatic metabolic CL (ml/min per kilogram)
1.7
0.80

Observed CL (ml/min per kilogram)
2.4
0.50

CLrenal (mL/min per kilogram)
<0.01 <0.01 CLbiliary (mL/min per kilogram) <0.01 0.04 In vivo/in vitro unbound CLintc 1.4 0.6 VSS (l/kg) 0.19 0.15 T1/2 (h) (PO) 1.3 3.7 (2.7) (8.4) F (%) 45 82

Reference

[1]. Gardiner P, et al. Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs. Drug Metab Dispos. 2019;47(8):865-873.
 [Content Brief]